Summary
Background: People with COVID-19 have increased risk of death and cardiometabolic disease including cardiovascular disease, diabetes mellitus, dyslipidemia and kidney disease. However, the evidence base is limited in 3 key aspects: (1) Existing studies have characterized the risks of adverse outcomes associated with earlier variants of SARS-CoV-2 and have limited follow-up. (2) It is not clear whether an annual vaccination for COVID-19 beyond the third dose reduces risk of adverse events. (3) Comparative analyses of COVID-19 vs. influenza are helpful to benchmarking risks but are only availabl
